![Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib](https://mms.businesswire.com/media/20220118006061/en/1106824/22/Merck_Logo_Horizontal_Teal%26Grey_RGB.jpg)
KEYTRUDA Significantly Improved Overall Survival (OS) in Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
Advertising Press Release Distribution | Reality TV | Lifestyle Magazine | Kiev Plastic Surgery
Advertising Business Newspaper | Miami News | Lifestyle Magazine | Fashion Magazine | Digital Newspaper | Lifestyle Magazine | Woman Magazine | Lifestyle News | Politic News | Miami News | Lifestyle Magazine | Politics News | Lifestyle Magazine Advertising Business Newspaper | Miami News | Lifestyle Magazine | Fashion Magazine | Digital Newspaper | Lifestyle Magazine | Woman Magazine | Lifestyle News | Politic News | Miami News | Lifestyle Magazine | Politics News | Lifestyle Magazine